uniQure N.V. $QURE Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its position in uniQure N.V. (NASDAQ:QURE) by 88.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,579 shares of the biotechnology company’s stock after selling 84,180 shares during the quarter. SG Americas Securities LLC’s holdings in uniQure were worth $617,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in QURE. Swiss National Bank purchased a new stake in shares of uniQure in the second quarter valued at about $1,080,000. Sanders Morris Harris LLC acquired a new position in shares of uniQure during the 3rd quarter worth approximately $5,081,000. Aberdeen Group plc lifted its stake in uniQure by 24.2% in the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after buying an additional 535,163 shares in the last quarter. Jennison Associates LLC acquired a new stake in uniQure during the 2nd quarter valued at $1,952,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in uniQure during the 2nd quarter valued at $872,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on QURE. The Goldman Sachs Group reduced their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. HC Wainwright decreased their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Royal Bank Of Canada cut their price objective on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Guggenheim upped their price objective on shares of uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Finally, UBS Group set a $95.00 price target on uniQure in a report on Thursday, September 25th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.82.

Insider Transactions at uniQure

In other uniQure news, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the transaction, the director owned 40,145 shares in the company, valued at $1,094,352.70. This represents a 43.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at $620,119.26. This trade represents a 65.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 102,247 shares of company stock worth $2,839,298. 4.79% of the stock is currently owned by insiders.

uniQure Stock Up 4.4%

QURE opened at $22.69 on Friday. The company has a market cap of $1.41 billion, a PE ratio of -5.17 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The firm has a 50 day moving average price of $24.22 and a 200 day moving average price of $27.94.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. Sell-side analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.